Deep characterization of the immunopeptidome can support the development of new therapeutics for cancer, immunological diseases, and infectious diseases. Biognosys’ Immunopeptidome Profiling solution consists of our proprietary, highly sensitive enrichment and identification of immunopeptides. We allow you to identify more than 10,000 Class I and 10,000 Class II peptides relevant for your drug discovery research.
The immunopeptidome represents the entirety of peptides presented by nucleated cells on HLA or MHC Class-I and Class-II proteins involved in the antigen-presentation pathway. It is essential in defining immunogenic epitopes in cell-mediated and humoral responses. Characterizing the immunopeptidome will enable you to discover targets for personalized cancer immunotherapies, such as neoantigens from tumor-specific mutations or tumor-associated antigens. Furthermore, novel mRNA and peptide-based vaccines and cell-based therapies can be developed.
We perform immunopeptidomics with our optimized high-throughput pipeline offering reproducible identification and quantification from minimal sample material.
The service can be applied in large-scale studies and is ideal for researchers looking for a standalone solution that digs deep into what is unknown but ready to be discovered.
“We were really impressed at the depth of peptide identification for both HLA I and II complexes from a small amount of cancer patient tissue. Thanks to quantitative MS, we can link biological hypothesis to quantification of neoantigen of interest.”
Jonathan Woodsmith, Ph.D.,
VP Advanced Analytics and AI, Indivumed
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel format.
a) Normalized data matrix of all quantified peptides/proteins
b) Peptide sequences and associates protein annotation
a) Characteristics of the peptide inventory
b) Hierarchical clustering analysis
c) Statistical testing to identify differentially expressed immunopeptides
d) Peptide-based PCA
e) Possibility of in-depth analysis of PTMs
f) Custom analysis upon request
Immunopeptidome Profiling can be applied to human tissues and cultured cells. Only a limited amount of material is required: 25 million cells or 10-15 mg fresh frozen tissue.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
Presenter: Luca Räss Oral Presentation at ASMS 2021
The case study elaborates on the latest study on lung cancer we performed with our high-throughput TrueDiscovery™ platform for immunopeptidome profiling from needle-sized biopsie [...]
Access our knowledge base with relevant resources and guiding information.